Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

RAHWAY, N.J. – Merck & Co., Inc., a global healthcare ... particularly in treating challenging forms of ovarian cancer. Currently, KEYTRUDA is not approved for the treatment of ovarian cancer ...

KEYTRUDA ® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS ...

“This marks the first time a Keytruda-based ... overall survival benefit in ovarian cancer,” said Dr Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.

Currently, KEYTRUDA is not approved for the treatment of ovarian cancer, but it has multiple approved indications in the United States for other cancers, including melanoma, non-small cell lung cancer ...